Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
20.2M
-
Shares change
-
-440K
-
Total reported value, excl. options
-
$88.5M
-
Value change
-
-$2.84M
-
Put/Call ratio
-
1.69
-
Number of buys
-
18
-
Number of sells
-
-33
-
Price
-
$4.39
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2018
80 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q3 2018.
AVADEL PHARMACEUTICALS - COM (AVDL) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.2M shares
.
Largest 10 shareholders include BRANDES INVESTMENT PARTNERS, LP (6.34M shares), Broadfin Capital, LLC (2.79M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.72M shares), ACADIAN ASSET MANAGEMENT LLC (1.12M shares), BROWN CAPITAL MANAGEMENT LLC (1.01M shares), Tekla Capital Management LLC (815K shares), MORGAN STANLEY (777K shares), DEUTSCHE BANK AG\ (777K shares), RENAISSANCE TECHNOLOGIES LLC (579K shares), and BlackRock Inc. (483K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.